Literature DB >> 12784398

Bactericidal/permeability-increasing protein and cathepsin G are the major antigenic targets of antineutrophil cytoplasmic autoantibodies in systemic sclerosis.

Dhanita Khanna1, Amita Aggarwal, Darshan S Bhakuni, Rajeshwar Dayal, Ramnath Misra.   

Abstract

OBJECTIVE: To study the prevalence and antigenic specificity of antineutrophil cytoplasmic autoantibodies (ANCA) in patients with systemic sclerosis (SSc).
METHODS: Sera from 68 patients with SSc were screened for ANCA by indirect immunofluorescence (IIF) assay and for antibodies to myeloperoxidase (MPO) by ELISA. All sera positive for ANCA on IIF were analyzed for reactivity against antigenic targets other than MPO [bactericidal/permeability-increasing protein (BPI), cathepsin G, lysozyme, elastase, PR3, and lactoferrin]. Twenty-three sera negative for ANCA were also tested for antibodies to BPI and cathepsin G using ELISA.
RESULTS: The study included 33 patients with diffuse and 35 with limited SSc. ANCA was detected in 24 of the 68 sera (35.3%). In these 24 sera the antigenic targets were BPI in 14, cathepsin G in 13, and MPO in 8. Sera of 11 patients had reactivity against both BPI and cathepsin G. In sera, that were negative for ANCA, antibodies to BPI (4/23), cathepsin G (3/23), and MPO (1/44) were found in a small proportion of patients. Patients with antibodies to BPI had lower skin score, whereas no patient with antibodies to MPO had renal disease.
CONCLUSION: BPI and cathepsin G are the major antigenic targets of ANCA seen in patients with SSc. Patients with antibodies to BPI had lower skin scores.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12784398

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  13 in total

1.  A 66-Year-Old Woman With Hemoptysis.

Authors:  Falin B Patel; Kara S Couch; Sean McNish; Jonathan D Miller; Robert Siegel; Samantha Easley; Victoria K Shanmugam
Journal:  Arthritis Care Res (Hoboken)       Date:  2017-03       Impact factor: 4.794

Review 2.  Autoantibodies in primary sclerosing cholangitis.

Authors:  Johannes-Roksund Hov; Kirsten-Muri Boberg; Tom-H Karlsen
Journal:  World J Gastroenterol       Date:  2008-06-28       Impact factor: 5.742

3.  Scleroderma associated with ANCA-associated vasculitis.

Authors:  Young Hee Rho; Seong Jae Choi; Young Ho Lee; Jong Dae Ji; Gwan Gyu Song
Journal:  Rheumatol Int       Date:  2005-07-13       Impact factor: 2.631

Review 4.  Scleroderma associated with ANCA-associated vasculitis.

Authors:  Young Hee Rho; Seong Jae Choi; Young Ho Lee; Jong Dae Ji; Gwan Gyu Song
Journal:  Rheumatol Int       Date:  2005-07-20       Impact factor: 2.631

Review 5.  ANCA-associated vasculitis with renal involvement.

Authors:  Valentina Binda; Gabriella Moroni; Piergiorgio Messa
Journal:  J Nephrol       Date:  2017-05-30       Impact factor: 3.902

6.  Microscopic polyangiitis in systemic sclerosis.

Authors:  Hiroshi Hashimoto
Journal:  Int J Rheumatol       Date:  2010-08-09

Review 7.  ANCA-associated vasculitis - clinical utility of using ANCA specificity to classify patients.

Authors:  Divi Cornec; Emilie Cornec-Le Gall; Fernando C Fervenza; Ulrich Specks
Journal:  Nat Rev Rheumatol       Date:  2016-07-28       Impact factor: 20.543

Review 8.  Antibodies in scleroderma: direct pathogenicity and phenotypic associations.

Authors:  Lorinda Chung; Paul J Utz
Journal:  Curr Rheumatol Rep       Date:  2004-04       Impact factor: 4.592

9.  Prevalence of overlap of antineutrophil cytoplasmic antibody associated vasculitis with systemic autoimmune diseases: an unrecognized example of poliautoimmunity.

Authors:  Eduardo Martín-Nares; Diego Zuñiga-Tamayo; Andrea Hinojosa-Azaola
Journal:  Clin Rheumatol       Date:  2018-07-14       Impact factor: 2.980

10.  Unclassifiable repeated antineutrophil cytoplasmic antibody (ANCA) positivity in diseases other than ANCA-associated vasculitis.

Authors:  Hyeok Choi; Yong-Beom Park; Jaewoo Song; Sang-Won Lee
Journal:  Z Rheumatol       Date:  2021-04-27       Impact factor: 1.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.